Kyowa Kirin

Kyowa Kirin Co., Ltd.
FormerlyKyowa Hakko Kogyo Co., Ltd. (1949–2008)
Company typePublic
TYO: 4151
Nikkei 225 Component
Industry
PredecessorKirin Pharma
FoundedJuly 1, 1949; 76 years ago (1949-07-01)
HeadquartersOhtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100–8185, Japan
Key people
Nobuo Hanai, (CEO and president)
Products
Revenue$ 2.99 billion USD (FY 2022) Increase (¥ 398.4 billion JPY) (FY 2022)
$ 375 million USD (FY 2022) Increase (¥ 53.6 billion JPY) (FY 2022)
Number of employees
7,532 (consolidated) (as of December 31, 2017)
ParentKirin Holdings Company, Limited
Subsidiaries47 (33 in Japan and 14 overseas countries)
WebsiteOfficial website
Footnotes / references
[1][2][3]

Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and was among the 40 largest in the world by revenue in 2012.[4] The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.[5]

History

The forerunner of the present-day company was called Kyowa Hakko Kogyo Co., Ltd (協和醱酵工業株式会社, lit. 'Coordinated Fermentation Industry Share Company') and was established on July 1, 1949. The company merged with Kirin Pharma Co., Ltd., on October 1, 2008 to form Kyowa Hakko Kirin (KHK) with plans to spin off the bio-chemical business into Kyowa Hakko Bio.[6]

On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million [7]

In 2019, Kirin Holdings acquired 95% stake in Kyowa Hakko Bio which is Kyowa Kirin's subsidiary corporation.[8] The entity was renamed "Kyowa Kirin Co., Ltd.", replacing its prior name of Kyowa Hakko Kirin Co., Ltd.

In November 2022, Kyowa Kirin announced plans to spin its International Established Medicines portfolio, consisting of 13 brands, into a new joint venture with German company Grünenthal.[9] The joint venture would expand Grüenthal's already extensive pain management portfolio, while Kyowa Kirin saw it as a financial benefit and an opportunity to expand the brands.[9]

In October 2023, Kyowa Kirin acquired a Britain-based biopharmaceutical company, Orchard Therapeutics, for $478 million, aiming to expand their portfolio.[10]

Business segments and products

Pharmaceuticals business

The company developed a method to make afucosylated monoclonal antibodies using a CHO cell line in which FUT8 has been knocked out; the company calls this its "Potelligent" platform. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform.[11]

Bio-Chemicals business

References

  1. ^ "Kyowa Hakko Kirin Company Overview". Kyowa Hakko Kirin. Retrieved March 14, 2014.
  2. ^ "Kyowa Hakko Kirin Corporate Profile" (PDF). Kyowa Hakko Kirin. Retrieved March 14, 2014.
  3. ^ "Kyowa Hakko Kirin Annual Report 2012". Kyowa Hakko Kirin. Retrieved March 14, 2014.
  4. ^ "Top 50 Pharma Companies by 2012 Revenue". Current Partnering. Wildwood Ventures Ltd. Archived from the original on February 8, 2014. Retrieved March 14, 2014.
  5. ^ "Components: Nikkei Stock Average (Nikkei 225)". Nikkei Stock Average (Nikkei 225). Nikkei Inc. January 30, 2026. Retrieved January 30, 2026.
  6. ^ "Kyowa Hakko Group and Kirin Group Announce Strategic Alliance". News. Kyowa USA. October 31, 2007. Retrieved January 30, 2026.[self-published source]
  7. ^ "ProStrakan Acquires Archimedes Pharma for $394M". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. July 11, 2014. Archived from the original on July 14, 2014. Retrieved January 20, 2015.
  8. ^ Reyes, Jean (February 6, 2019). "Kirin to acquire 95% stake in Kyowa Hakko Bio". S&P Global Market Intelligence. Archived from the original on December 29, 2021.
  9. ^ a b "Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio" (Press release). Business Wire. November 24, 2022. Retrieved January 30, 2026.
  10. ^ "Kyowa Kirin to acquire Orchard Therapeutics for $478 million". Reuters. October 5, 2023. Retrieved October 5, 2023.
  11. ^ Yu, X; Marshall, MJE; Cragg, MS; Crispin, M (June 2017). "Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering" (PDF). BioDrugs. 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278. S2CID 3722081.
  12. ^ "FY 2013 Consolidated Financial Summary". Kyowa Hakko Kirin. Archived from the original on March 4, 2016. Retrieved March 14, 2014.
allikas: http://en.wikipedia.org/wiki/Kyowa_Hakko